SCHEMBL15827140

SCHEMBL15827140

O=C1/C(=C/c2ccc(-c3ccc(Cl)cc3Cl)o2)SC(=S)N1c1cccc(F)c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAP3K5 Q99683 9/20 0.53
INSR P06213 1/20 0.51
IGF1R P08069 1/20 0.51
ITGB2 P05107 2/20 0.50
ITGAM P11215 2/20 0.50
GSK3A P49840 1/20 0.49
GSK3B P49841 1/20 0.49
MAPT P10636 3/20 0.48
MEN1 O00255 3/20 0.48
KMT2A Q03164 3/20 0.48
KDM4E B2RXH2 2/20 0.48
MAPK1 P28482 2/20 0.48
RECQL P46063 2/20 0.48
TDP1 Q9NUW8 2/20 0.48
ALDH1A1 P00352 1/20 0.48
LMNA P02545 1/20 0.48
POLB P06746 1/20 0.48
GAA P10253 1/20 0.48
SAE1 Q9UBE0 1/20 0.48
UBA2 Q9UBT2 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14860726 1.00 MAP3K5 (0.53) MAP3K5INSRIGF1RITGB2ITGAM
SCHEMBL14860725 1.00 MAP3K5 (0.53) MAP3K5INSRIGF1RITGB2ITGAM
SCHEMBL14860691 0.88 CFTR (0.55) MAP3K5INSRIGF1RITGB2ITGAM
SCHEMBL21634346 0.88 CFTR (0.55) MAP3K5INSRIGF1RITGB2ITGAM
SCHEMBL15827152 0.88 CFTR (0.55) MAP3K5INSRIGF1RITGB2ITGAM
SCHEMBL14860690 0.88 CFTR (0.55) MAP3K5INSRIGF1RITGB2ITGAM
SCHEMBL3895153 0.84 MEN1 (0.54) MAP3K5INSRIGF1RITGB2ITGAM
SCHEMBL3895157 0.84 MEN1 (0.54) MAP3K5INSRIGF1RITGB2ITGAM
SCHEMBL15827150 0.83 MAP3K5 (0.56) MAP3K5INSRIGF1RMAPTMEN1
SCHEMBL14860667 0.83 MAP3K5 (0.56) MAP3K5INSRIGF1RMAPTMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210228548-A1 PHARMACEUTICAL COMPOSITION FOR PREVENTING, ALLEVIATING OR TREATING OSTEOARTHRITIS, CONTAINING RHODANINE DERIVATIVE AS ACTIVE INGREDIENT AVIXGEN INC. (KR) 2021-07-29 US disclosed
EP-3827827-A1 PHARMACEUTICAL COMPOSITION FOR PREVENTING, ALLEVIATING OR TREATING OSTEOARTHRITIS, CONTAINING RHODANINE DERIVATIVE AS ACTIVE INGREDIENT Avixgen Inc. (KR) 2021-06-02 EP disclosed
US-8759536-B2 Rhodanine derivatives, method for preparing same, and pharmaceutical composition for the prevention or treatment of aids containing the rhodanine derivatives as active ingredients AVIXGEN INC. (KR) 2014-06-24 US disclosed
US-8759536-B2 Rhodanine derivatives, method for preparing same, and pharmaceutical composition for the prevention or treatment of aids containing the rhodanine derivatives as active ingredients AVIXGEN INC. (KR) 2014-06-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210228548-A1 PHARMACEUTICAL COMPOSITION FOR PREVENTING, ALLEVIATING OR TREATING OSTEOARTHRITIS, CONTAINING RHODANINE DERIVATIVE AS ACTIVE INGREDIENT COL2A1, COL1A1, SYVN1 MAP3K5 3896/4885INSR 4549/4885IGF1R 3324/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.